199
Views
6
CrossRef citations to date
0
Altmetric
Patent Evaluations

New selective inhibitors of MMP-13 for inflammatory diseases: a patent evaluation (W02012151158)

, &
Pages 669-675 | Published online: 19 Mar 2013

Bibliography

  • Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002;14:573-7
  • Wollheim FA. Current pharmacological treatment of osteoarthritis. Drugs 1996;52:27-38
  • McAlindon T. Glusoamine for osteoarthritis: dawn of a new era? Lancet 2001;357:247-8
  • Chard J, Dieppe P. Glucosamine for osteoarthritis: magic, hype, or confusion? BMJ 2001;322:1439-40
  • Reginster JY, Deroisy R, Rovati LC, Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6
  • Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4
  • Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 2008;4:128-35
  • Li NG, Shi ZH, Tang YP, Duan JA. Selective matrix metalloproteinase inhibitors for cancer. Curr Med Chem 2009;16:3805-27
  • Johnson AR, Pavlovsky AG, Ortwine DF, Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007;282:27781-91
  • Billinghurst RC, Dahlberg L, Ionescu M, Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45
  • Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92
  • Levitt NC, Eskens FALM, O'Byrne KJ, Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7:1912-22
  • Li NG, Shi ZH, Tang YP, New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem 2011;18:977-1001
  • Li W, Hua Y, Li J, 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding. Bioorg Med Chem Lett 2009;19:4546-50
  • Kolodziej SA, Hockerman SL, DeCrescenzo GA, MMP-13 selective isonipecotamide alpha-sulfone hydroxamates. Bioorg Med Chem Lett 2010;20:3561-4
  • Gao DA, Xiong Z, Heim-Riether A, SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability. Bioorg Med Chem Lett 2010;20:5039-43
  • Savi CD, Morley AD, Nash I, Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2. Bioorg Med Chem Lett 2012;22:271-7
  • Blagg JA, Noe MC, Wolf-Gouveia LA, Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 2005;15:1807-10
  • McGeehan GM, Becherer JD, Bast RC, Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994;370:558-61
  • Peschon JJ, Slack JL, Reddy P, An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-4
  • Gallea-Robache S, Morand V, Millet S, A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 1997;9:340-6
  • Hooper NM, Kariran EH, Turner AJ. Membrane protein secretases. Biochem J 1997;321:265-79
  • Montana J, Baxter A. The design of selective non-substrate-based matrix metalloproteinase inhibitors. Curr Opin Drug Discov Devel 2000;3:353-61
  • Rubino MT, Agamennone M, Campestre C, Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors. ChemMedChem 2009;4:352-62
  • Agrawal A, Romero-Perez D, Jacobsen JA, Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 2008;3:812-20

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.